Table 2.
Clinical related characteristics of HIV infected patients treated at Woldia and Dessie hospitals, 2018
| Variables | Category | Cases(n=154) | Controls (n=154) | p-value for Chi-square test |
|---|---|---|---|---|
| Frequency (%) | Frequency (%) | |||
| Baseline body mass index (BMI ) | <16 | 14 (9.1) | 16 (10.4) | 0.349 |
| 16-18.5 | 44 (28.6) | 33 (21.4) | ||
| >18.5 | 96 (62.3) | 105 (68.2) | ||
| Current BMI | <16 | 27 (17.5) | 10 (6.5) | < 0.001 |
| 16-18.5 | 37 (24) | 12 (7.8) | ||
| >18.5 | 90 (58.4) | 132 (85.7) | ||
| Baseline CD4 T-cell count | ≤ 200 | 98 (63.6) | 91 (59.1) | 0.413 |
| >200 | 56 (36.4) | 63 (40.9) | ||
| Current CD4 T-cell count | ≤ 200 | 62 (40.3) | 30 (19.5) | <0.001 |
| >200 | 92 (59.7) | 124 (80.5) | ||
| Base line Hgb(g/dl) | ≤12 | 51 (33.1) | 43 (27.9) | 0.322 |
| >12 | 103 (66.9) | 111 (72.1) | ||
| Functional status | Working | 85 (55.2) | 89 (57.8) | 0.295 |
| Ambulatory | 64 (41.6) | 55 (35.7) | ||
| Bedridden | 5 (3.2) | 10 (6.5) | ||
| WHO staging at baseline | stage 1 | 17 (11) | 27 (17.5) | 0.347 |
| stage 2 | 57 (37) | 50 (32.5) | ||
| stage 3 | 66 (42.9) | 60 (39) | ||
| stage 4 | 14 (9.1) | 17 (11) | ||
| Treatment staginga | T1 stage | 140 (90.9) | 135 (87.7) | 0.643 |
| T2 stage | 10 (6.5) | 13 (8.4) | ||
| T3 stage | 4 (2.6) | 6 (3.9) | ||
| HIV durationb | <24 months | 7 (4.5) | 7 (4.5) | 0.985 |
| 24-48 months | 19 (12.3) | 20 (13) | ||
| >48 months | 128 (83) | 127 (82.5) | ||
| TB before starting ART | Yes | 28 (18.2) | 34 (22) | 0.394 |
| No | 126 (81.8) | 120 (78) | ||
| TB after starting ART | Yes | 3 (2) | 2 (1.3) | 0.652 |
| No | 151 (98) | 152 (98.7) |
aClinical stage of HIV patients after starting antiretroviral treatment
bthe time includes both before and after starting ART following first HIV positive test